References
- Jung JA , LimHS . Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis . Pharmacogenomics15 ( 1 ), 49 – 60 ( 2014 ).
- Province MA , GoetzMP , BrauchHet al. CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations . Clin. Pharmacol. Ther.95 ( 2 ), 216 – 227 ( 2014 ).
- Johnson JA , HamadehIS , LangaeeTY . Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies . J. Natl Cancer Inst.107 ( 2 ), pii. dju437 ( 2015 ).
- Goetz MP , SunJX , SumanVJet al. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies . J. Natl Cancer Inst.107 ( 2 ), pii. dju401 ( 2014 ).
- Rae JM , ReganMM , ThibertJNet al. Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA . J. Natl Cancer Inst.105 ( 17 ), 1332 – 1334 ( 2013 ).
- Ratain MJ , NakamuraY , CoxNJ . CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality . Clin. Pharmacol. Ther.94 ( 2 ), 185 – 187 ( 2013 ).